Intuitive Surgical (NASDAQ:ISRG) Stock Price Target Cut by Mizuho

Key Points

• Mizuho lowered Intuitive Surgical’s price target from $415 to $400 and maintained a “neutral” rating, implying 8.68% downside from the prior close.
• Analyst sentiment remains broadly positive: 25 analysts rate the stock a Buy, with an average target of $500.57 and an overall “Moderate Buy” consensus.
• Recent quarterly results exceeded expectations, with revenue rising 21.7% year over year to $3.05 billion and earnings reaching $3.00 per share versus a $2.65 consensus estimate.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) had its price objective reduced by stock analysts at Mizuho from $415.00 to $400.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a "neutral" rating on the medical equipment provider's stock. Mizuho's target price suggests a potential downside of 8.68% from the company's previous close.

Other analysts have also recently issued reports about the company. Leerink Partners cut their price target on Intuitive Surgical from $573.00 to $454.00 and set an "outperform" rating on the stock in a research note on Friday, July 17th. BNP Paribas Exane raised Intuitive Surgical to an "outperform" rating in a research report on Tuesday, July 28th. Raymond James Financial reaffirmed an "outperform" rating and set a $480.00 price objective on shares of Intuitive Surgical in a research report on Wednesday. Wall Street Zen downgraded Intuitive Surgical from a "buy" rating to a "hold" rating in a report on Sunday, September 20th. Finally, Barclays reissued an "overweight" rating and set a $500.00 target price on shares of Intuitive Surgical in a research report on Wednesday. Twenty-five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has an average rating of "Moderate Buy" and an average target price of $500.57.

Intuitive Surgical Trading Up 1.1%

Shares of ISRG opened at $438.00 on Wednesday. Intuitive Surgical has a twelve month low of $328.57 and a twelve month high of $603.88. The firm's fifty day simple moving average is $392.96 and its 200-day simple moving average is $409.06. The firm has a market capitalization of $154.74 billion, a price-to-earnings ratio of 50.17, a PEG ratio of 3.27 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.35. The business had revenue of $3.05 billion during the quarter, compared to analysts' expectations of $2.91 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company's revenue for the quarter was up 21.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.40 EPS. On average, analysts predict that Intuitive Surgical will post 8.87 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $379.00, for a total transaction of $151,600.00. Following the sale, the executive vice president owned 5,320 shares in the company, valued at approximately $2,016,280. The trade was a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of Intuitive Surgical stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total value of $407,765.16. Following the sale, the vice president owned 1,026 shares in the company, valued at $384,175.44. This trade represents a 51.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock valued at $4,891,989 over the last quarter. 0.60% of the stock is owned by corporate insiders.

Institutional Trading of Intuitive Surgical

A number of large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in Intuitive Surgical in the second quarter valued at about $1,335,753,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Intuitive Surgical by 95.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock valued at $970,635,000 after acquiring an additional 1,027,475 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Intuitive Surgical by 55.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,557,940 shares of the medical equipment provider's stock worth $633,505,000 after acquiring an additional 558,099 shares in the last quarter. Amundi boosted its stake in shares of Intuitive Surgical by 8.6% during the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider's stock worth $1,119,448,000 after acquiring an additional 193,096 shares in the last quarter. Finally, Temasek Holdings Private Ltd boosted its stake in shares of Intuitive Surgical by 416.4% during the 1st quarter. Temasek Holdings Private Ltd now owns 227,211 shares of the medical equipment provider's stock worth $104,742,000 after acquiring an additional 183,211 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q3 results exceeded expectations: Revenue rose 21.7% year over year to $3.05 billion, above the approximately $2.91 billion consensus, while adjusted earnings reached $3.00 per share versus estimates of roughly $2.61–$2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Underlying demand remained healthy: Worldwide procedures increased approximately 15%, including 14% growth for da Vinci procedures and 31% for Ion procedures. Intuitive placed 546 robotic systems, up from 427 a year earlier. Intuitive Announces Third Quarter Earnings
• Positive Sentiment: Potentially broader adoption: Intuitive plans to extend instrument life and reduce per-procedure costs in 2027. Although this could pressure near-term revenue per procedure, management views it as a way to make robotic surgery more affordable and expand the installed base. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
• Neutral Sentiment: Leasing is supporting placements: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it can also make Intuitive’s returns more dependent on future procedure volume. Does Leasing Make Growth More Durable or More Capital Intensive?
• Negative Sentiment: Large antitrust settlement charge hurt GAAP earnings: Intuitive recorded a $450 million pre-tax charge, or $347 million after tax, related to a proposed settlement. GAAP net income fell to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier; court approval is still required. Antitrust Settlement Charge Overshadows Strong Q3 Growth
• Negative Sentiment: 2026 procedure-growth guidance was narrowed to 14%–15%: The tighter outlook, along with planned pricing actions targeting a 3%–5% reduction in instrument and accessory costs per procedure, raised concerns that growth and margins may moderate. Intuitive Narrows 2026 Procedure Growth Outlook

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.